Anodyne Raises $12.6M to Replace Weekly GLP-1 Injections With a Skin Patch
Boston biotech Anodyne Nanotech secures Series A funding to advance a once-weekly GLP-1 obesity patch into first human trials.
1,333 articles
Boston biotech Anodyne Nanotech secures Series A funding to advance a once-weekly GLP-1 obesity patch into first human trials.
FDA Breakthrough Designation for fosigotifator validates the Integrated Stress Response as a real therapeutic target in neurodegeneration and aging.
A overlooked odd-chain fatty acid called C15 is challenging decades of blanket anti-fat dietary advice and attracting longevity researchers.
UCLA researchers found long-term chlorpyrifos exposure more than doubles Parkinson's risk and damages dopamine neurons directly.
A 6-month study found HIIT uniquely protects lean muscle in adults in their 70s, while moderate and low-intensity exercise caused small muscle losses.
A once-daily oral drug significantly increased height velocity in children with achondroplasia, offering an alternative to daily injections.
A potent bispecific antibody showed faster vision gains than a leading rival in a 164-patient trial, now heading to global Phase 3.
Multiple major studies converge on a sobering conclusion: life expectancy gains are slowing and radical life extension may be biologically implausible.
A landmark study of 463,000 teens found cannabis use doubles the risk of psychotic and bipolar disorders by young adulthood.
A modified B12 molecule delivers nitric oxide directly to glioblastoma tumors and boosts existing treatments in animal and lab studies.
Johns Hopkins scientists found brainstem neurons that filter distractions in mice, offering new clues to treating ADHD and attention disorders.
Scientists identify a new type of stem cell that activates with aging and supercharges belly fat production, opening anti-obesity targets.